We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > JAK inhibitor

News List

From Ruxolitinib to Upadacitinib, the USD 5 Billion Blue Ocean Market Ushers a Fierce Battle of JAK Inhibitors Spuer 203
May 06, 2024
Medical System from Incyte has initiated Phase III clinical trials of vitiligo in China.
Gilead’s oral JAK inhibitor filgotinib wins EU approval pharmatimes
September 30, 2020
Gilead Science’s Galapagos-partnered oral JAK inhibitor filgotinib has been approved by the European Commission under the brand name Jyseleca for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
AbbVie’s JAK inhibitor upadacitinib gets Priority Review pharmaphorum
February 21, 2019
AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).
Theravance Biopharma Announces First Patient Dosed in TD-1473 Study americanpharmaceuticalreview
December 27, 2018
Theravance Biopharma announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease. TD-1473 is a novel, potent, orally administered and ......